Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?

Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer.

UNLABELLED Multicentric or multifocal breast cancer is considered as one of the limitations for sentinel lymph node (SLN) localization. We did a retrospective analysis to evaluate the success rate, sensitivity, accuracy, and negative predictive values of SLN localization in multicentric or multifocal breast lesions. METHODS Fifty-nine patients with multifocal or multicentric breast lesions pr...

Assessment of the Prognostic Role of HER2 Overexpression in Patients with Node-Negative, pT1a-b Breast Cancer

Perspectives of Cosmesis following Breast Conservation for Multifocal and Multicentric Breast Cancers

Background. Contemporary data suggest that breast conservation treatment (BCT) for multifocal and multicentric breast cancer (MFMCBC) may be appropriate with noninferior local control rates. However, there is a paucity of data to evaluate patient's satisfaction with cosmetic outcomes after BCT for MFMCBC. This study was performed to bridge this information gap. Methods. All patients treated at ...

HER2 Intermediate Breast Cancers.

To the Editor: We were interested to read the article by Gilcrease et al ‘‘Even low level Her2 expression may be associated with worse outcome in node positive breast cancer’’ that discusses the significance of low but nonnegative Her2 protein levels in the prognosis of breast cancer. As the authors note, the conventional immunohistochemical scoring system for Her2 includes cases with 1+ expres...

Does lapatinib work against HER2-negative breast cancers?

Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.